These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11958989)

  • 21. QSAR by LFER model of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA, and PLS techniques.
    Leonard JT; Roy K
    Bioorg Med Chem; 2006 Feb; 14(4):1039-46. PubMed ID: 16213730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
    Koda Y; Kikuzato K; Mikuni J; Tanaka A; Yuki H; Honma T; Tomabechi Y; Kukimoto-Niino M; Shirouzu M; Shirai F; Koyama H
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4994-4998. PubMed ID: 29037944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena.
    Kaspersen SJ; Sundby E; Charnock C; Hoff BH
    Bioorg Chem; 2012 Oct; 44():35-41. PubMed ID: 22832269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
    Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
    Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationship for the binding of nucleoside ligands to adenosine kinase from Toxoplasma gondii.
    Iltzsch MH; Uber SS; Tankersley KO; el Kouni MH
    Biochem Pharmacol; 1995 May; 49(10):1501-12. PubMed ID: 7763293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5,6,7-trisubstituted 4-aminopyrido[2,3-d]pyrimidines as novel inhibitors of adenosine kinase.
    Perner RJ; Gu YG; Lee CH; Bayburt EK; McKie J; Alexander KM; Kohlhaas KL; Wismer CT; Mikusa J; Jarvis MF; Kowaluk EA; Bhagwat SS
    J Med Chem; 2003 Nov; 46(24):5249-57. PubMed ID: 14613327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, screening and quantitative structure-activity relationship (QSAR) studies of some glutamine analogues for possible anticancer activity.
    Srikanth K; Kumar ChA; Ghosh B; Jha T
    Bioorg Med Chem; 2002 Jul; 10(7):2119-31. PubMed ID: 11983508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.
    Ugarkar BG; DaRe JM; Kopcho JJ; Browne CE; Schanzer JM; Wiesner JB; Erion MD
    J Med Chem; 2000 Jul; 43(15):2883-93. PubMed ID: 10956196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
    Müller CE; Geis U; Grahner B; Lanzner W; Eger K
    J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New lead elements for histamine H
    Espinosa-Bustos C; Frank A; Arancibia-Opazo S; Salas CO; Fierro A; Stark H
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2890-2893. PubMed ID: 30025902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of clitocine analogues as adenosine kinase inhibitors.
    Lee CH; Daanen JF; Jiang M; Yu H; Kohlhaas KL; Alexander K; Jarvis MF; Kowaluk EL; Bhagwat SS
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2419-22. PubMed ID: 11549437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyridopyrimidine analogues as novel adenosine kinase inhibitors.
    Zheng GZ; Lee C; Pratt JK; Perner RJ; Jiang MQ; Gomtsyan A; Matulenko MA; Mao Y; Koenig JR; Kim KH; Muchmore S; Yu H; Kohlhaas K; Alexander KM; McGaraughty S; Chu KL; Wismer CT; Mikusa J; Jarvis MF; Marsh K; Kowaluk EA; Bhagwat SS; Stewart AO
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2071-4. PubMed ID: 11514141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and synthesis of substituted pyrrolo[2,3-d]pyrimidines as novel firefly luciferase inhibitors.
    Liu Y; Fang J; Cai H; Xiao F; Ding K; Hu Y
    Bioorg Med Chem; 2012 Sep; 20(18):5473-82. PubMed ID: 22898255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.
    Oguro Y; Miyamoto N; Okada K; Takagi T; Iwata H; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
    Bioorg Med Chem; 2010 Oct; 18(20):7260-73. PubMed ID: 20833055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of Novel 5,6-Disubstituted Pyrrolo [2,3-d]Pyrimidine-2,4-Diones Via One-Pot Three-Component Reactions.
    Karamthulla S; Jana A; Choudhury LH
    ACS Comb Sci; 2017 Feb; 19(2):108-112. PubMed ID: 28036166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel synthesis, properties, and NAD+-NADH type redox ability of 1,3-dimethylcyclohepta[4,5]pyrrolo[2,3-d]pyrimidine- 2,4(1,3h)-dionylium ions annulated with additional pyrrolo[2,3-d]pyrimidine-1,3(2,4h)-dione and furan analogue, and their hydride adducts.
    Naya S; Nishimura J; Nitta M
    J Org Chem; 2005 Nov; 70(24):9780-8. PubMed ID: 16292806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
    Chamberlain SD; Redman AM; Wilson JW; Deanda F; Shotwell JB; Gerding R; Lei H; Yang B; Stevens KL; Hassell AM; Shewchuk LM; Leesnitzer MA; Smith JL; Sabbatini P; Atkins C; Groy A; Rowand JL; Kumar R; Mook RA; Moorthy G; Patnaik S
    Bioorg Med Chem Lett; 2009 Jan; 19(2):360-4. PubMed ID: 19071018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.